LACTOLOGY FOUNDATION

Clinical and Pathophysiological Analysis of Food Hypersensitivity: Diagnostic Standards, Disease-Modifying Therapeutics, and Preventive Frameworks

The landscape of clinical allergy and immunology has undergone a substantial paradigm shift over the past two decades. Food allergy was historically conceptualized as a static, reactive condition managed primarily through strict allergen avoidance and emergency rescue medication. However, contemporary evidence classifies food hypersensitivity as a complex, dynamic spectrum of immunologically mediated disorders. The rising global prevalence of allergic conditions—often accompanying the "atopic march"—underscores the critical need for mechanistic precision, standardized diagnostic frameworks, and proactive therapeutic management. Distinguishing true immunologic hypersensitivity from non-immunologic adverse food reactions is essential to prevent overdiagnosis, mitigate unnecessary dietary restrictions, and safeguard pediatric growth and nutrition.

Classification and Epidemiology

Adverse reactions to ingested foods are broadly categorized into non-immunologic food intolerances and immunologically mediated food hypersensitivities. Food intolerance represents an abnormal physiological response driven by mechanisms independent of the immune system. These encompass toxic exposure, such as scombroid fish poisoning from histamine accumulation or bacterial enterotoxins from Salmonella and Campylobacter; pharmacologic properties of food constituents, including caffeine in beverages or tyramine in aged cheeses; host metabolic deficiencies, such as primary or acquired lactase deficiency; and idiosyncratic reactions.

Food hypersensitivity (food allergy) denotes an immunologically mediated reaction triggered by the ingestion of a specific food protein at doses tolerated by non-allergic individuals. Although up to 15% of the general population report adverse reactions to foods, objective epidemiological evaluations demonstrate an actual prevalence of 3% to 4% in adults and 6% to 8% in pediatric populations. The distribution of offending allergens varies by age: infants and young children predominantly react to hen's egg, cow's milk, peanut, soy, and wheat, whereas older children and adults most frequently manifest hypersensitivity to tree nuts, peanuts, fish, and shellfish.

Immunological Pathophysiology

Immune homeostasis within the gastrointestinal mucosa depends on the successful establishment and maintenance of oral tolerance—a state of local and systemic active non-responsiveness to non-pathogenic dietary proteins. Food hypersensitivity develops when oral tolerance fails to form during early development or breaks down later in life in genetically susceptible individuals.

In classical IgE-mediated (Type I) hypersensitivity, epicutaneous or mucosal antigen-presenting cells ingest, process, and present food allergens to naïve T helper cells. In an environment enriched with interleukin-4 (IL-4) and interleukin-13 (IL-13), these cells differentiate into $T_H2$ cells, promoting immunoglobulin class-switching in B lymphocytes toward antigen-specific IgE production. Circulating food-specific IgE molecules bind high-affinity receptors ($Fc\epsilon RI$) on tissue mast cells and circulating basophils, as well as low-affinity receptors ($Fc\epsilon RII$) on macrophages, eosinophils, and platelets.

Upon subsequent oral exposure, multivalent dietary proteins cross-link receptor-bound IgE molecules, triggering immediate mast cell and basophil degranulation. Preformed inflammatory mediators, primarily histamine and tryptase, alongside rapidly synthesized lipid-derived mediators—including prostaglandin $D_2$ ($PGD_2$), cysteinyl leukotrienes ($LTC_4, LTD_4, LTE_4$), and platelet-activating factor (PAF)—are released into adjacent tissues. These chemical mediators induce smooth muscle contraction, vasodilation, hypersecretion of mucus, and increased vascular permeability. Activated mast cells simultaneously secrete cytokines such as IL-5 and TNF-$\alpha$, driving the late-phase recruitment of eosinophils and neutrophils that sustain tissue inflammation.

In non-IgE-mediated food allergies, pathomechanisms are mediated predominantly by cell-mediated (Type IV) immune responses. Ingested proteins activate antigen-specific T cells, which migrate to the gut mucosa and recruit monocytes, macrophages, and eosinophils. This sustained cellular infiltration causes mucosal inflammation, villous blunting, altered microvascular permeability, and motility dysregulation. Mixed IgE- and non-IgE-mediated disorders reflect a dual immunopathological mechanism, combining immediate IgE-driven mast cell responses with chronic cellular inflammation and tissue eosinophilia.

Spectrum of Clinical Syndromes

IgE-Mediated Disorders

IgE-mediated reactions manifest rapidly, with symptoms typically appearing within minutes to two hours following allergen ingestion. Symptoms can involve the gastrointestinal tract, skin, respiratory system, and cardiovascular system.

Pollen-Food Allergy Syndrome (PFAS), or Oral Allergy Syndrome (OAS), represents a form of contact urticaria largely confined to the oropharynx. It arises from immunologic cross-reactivity between airborne pollen proteins (such as birch, ragweed, or grass pollens) and homologous, heat-labile proteins in raw fruits, vegetables, and nuts. Ingestion precipitates immediate localized pruritus, tingling, and mild angioedema of the lips, tongue, palate, and pharynx. Because these cross-reactive plant proteins are easily denatured by gastric acid and thermal processing, systemic symptoms or reactions to cooked forms are uncommon.

Immediate gastrointestinal hypersensitivity presents as acute postprandial nausea, severe abdominal cramping, emesis, and diarrhea. In infants with chronic atopic conditions, persistent daily allergen ingestion can induce partial desensitization of gastrointestinal mast cells, shifting clinical manifestations from acute emesis to subacute feeding intolerance and chronic abdominal discomfort.

Cutaneous manifestations, specifically acute urticaria and angioedema, are the most frequent presentations of immediate food hypersensitivity. IgE-mediated angioedema causes deep dermal and subcutaneous swelling. It must be distinguished clinically from bradykinin-mediated angioedema—such as hereditary C1-esterase inhibitor deficiency or angiotensin-converting enzyme (ACE) inhibitor-induced edema—which presents without pruritus or urticarial wheals.

Systemic anaphylaxis represents the most severe manifestation of IgE-mediated food allergy. It is a life-threatening, multi-system emergency characterized by laryngeal edema (stridor), bronchospasm (wheezing), severe hypotension, abdominal cramps, and vascular collapse. Anaphylaxis is defined by systemic airway, respiratory, or cardiovascular compromise, even in the complete absence of skin manifestations, which are absent in up to 50% of cases. Major risk factors for fatal food-induced anaphylaxis include underlying asthma (particularly if poorly controlled), adolescent or young adult age, delayed administration of epinephrine, and allergies to peanuts, tree nuts, fish, or shellfish.

Mixed IgE and Non-IgE Disorders

Allergic Eosinophilic Gastrointestinal Disorders (EGIDs), including Eosinophilic Esophagitis (EoE), Eosinophilic Gastritis, and Eosinophilic Gastroenteritis, are characterized by patchy or diffuse eosinophilic infiltration of the gastrointestinal wall in the absence of secondary causes of tissue eosinophilia. Clinical manifestations depend on the depth and location of cellular infiltration: mucosal disease leads to anorexia, postprandial emesis, abdominal pain, failure to thrive in infants, weight loss, iron deficiency anemia, and protein-losing enteropathy; muscularis involvement induces gut wall thickening, dysmotility, and luminal strictures; subserosal infiltration manifests as eosinophilic ascites. Microscopic evaluation of stool samples frequently reveals Charcot-Leyden crystals.

Non-IgE-Mediated Disorders

Food Protein-Induced Enterocolitis Syndrome (FPIES) is a severe, cell-mediated gastrointestinal disorder presenting predominantly in young infants between 1 week and 3 months of age. Common triggers include cow's milk or soy protein formula, as well as solid foods such as rice, oat, or poultry. Ingestion triggers severe, repetitive emesis 1 to 4 hours post-feeding, followed by diarrhea 5 to 8 hours later. Stools frequently contain occult blood, polymorphonuclear leukocytes, and eosinophils, testing positive for reducing substances due to secondary carbohydrate malabsorption. Severe FPIES episodes can cause severe dehydration, hypovolemic shock, methemoglobinemia, and metabolic acidosis. Skin prick tests and serum food-specific IgE assays are characteristically negative.

Dietary-Protein Proctitis (Food Protein-Induced Allergic Proctocolitis) presents during the first few months of life, frequently in exclusively breastfed infants exposed to maternally ingested cow's milk or soy proteins. Infants typically appear healthy, remain active, and display normal weight gain, presenting primarily with gross hematochezia mixed with mucus in formed stools. Histopathology shows eosinophilic infiltration of the rectosigmoid lamina propria and epithelial layer. Symptoms resolve rapidly upon eliminating the offending protein from the maternal or infant diet.

Celiac disease is a chronic autoimmune enteropathy driven by a cell-mediated (Type IV) hypersensitivity to dietary gluten (specifically the alcohol-soluble gliadin fraction found in wheat, rye, and barley) in genetically susceptible individuals expressing HLA-DQ2 or HLA-DQ8. Gluten ingestion induces intraepithelial lymphocytosis, crypt hyperplasia, and progressive villous atrophy, leading to malabsorption, chronic diarrhea, steatorrhea, abdominal distention, and systemic nutritional deficiencies.

Diagnostic Evaluation and Risk Stratification

Diagnostic evaluation requires a systematic approach combining a detailed history, selective diagnostic testing, exclusion diets, and controlled allergen challenges.

The diagnostic workup begins with a comprehensive medical history detailing the specific food ingested, estimated quantity, time elapsed between ingestion and symptom onset, target-organ manifestations, reaction consistency across exposures, presence of clinical cofactors (e.g., exercise, alcohol, NSAIDs), and time elapsed since the most recent reaction. Diet diaries provide a prospective chronological account of all ingested foods and associated symptoms, occasionally identifying unsuspected associations. Diagnostic elimination diets involve removing suspected proteins for a defined period. Symptomatic resolution should occur within 1 to 2 weeks in immediate IgE-mediated conditions, whereas chronic gastrointestinal disorders may require 6 to 12 weeks of elimination for complete mucosal healing.

Skin Prick Testing (SPT) introduces glycerinated food extracts epicutaneously alongside histamine (positive) and saline (negative) controls. A wheal diameter at least $3\text{ mm}$ greater than the negative control at 15 minutes defines a positive result. SPT exhibits high negative predictive accuracy ($>95\%$), making a negative test effective for ruling out IgE-mediated hypersensitivity. However, positive predictive accuracy is under 50%, as a positive wheal indicates allergic sensitization rather than confirmed clinical reactivity. Testing fresh fruits and vegetables often requires the "prick-by-prick" method to preserve unstable, heat-labile proteins that degrade in commercial extracts. Intradermal skin testing has no role in food allergy diagnostics due to low specificity and an elevated risk of systemic anaphylaxis.

Quantitative measurement of serum allergen-specific IgE antibodies using capsulated hydrophilic carrier polymer fluoroenzyme immunoassays (CAP-FEIA / ImmunoCAP) offers reproducible in vitro data. Serum IgE testing is preferred when skin testing is unsafe or impractical, such as in patients with widespread severe dermatitis, dermatographism, recent anaphylaxis, or those unable to discontinue interfering medications like antihistamines or tricyclic antidepressants.

Validated decision thresholds for serum allergen-specific IgE concentrations predict clinical reactivity with a positive predictive value (PPV) exceeding 95%, reducing the need for oral food challenges in high-probability cases.

A critical responsibility in clinical allergy practice is distinguishing evidence-based diagnostics from unvalidated or misleading assays. Assays such as food-specific serum IgG or IgG4 panels, food-antigen immune complex testing, cytotoxic blood tests, leukocyte histamine release assays, sublingual provocation-neutralization, and hair analysis lack clinical validity. Serum IgG4 antibodies reflect physiological exposure and immune tolerance following antigen ingestion rather than pathological hypersensitivity. Reliance on unvalidated IgG panels leads to inappropriate dietary restrictions, malnutrition, and unnecessary anxiety.

The Double-Blind, Placebo-Controlled Food Challenge (DBPCFC) remains the diagnostic gold standard in research and clinical settings. DBPCFC eliminates observer bias, placebo responses, and psychogenic factors. Single-blind or open food challenges are frequently utilized in routine practice when the likelihood of a reaction is low or when objective parameters are monitored.

Updated consensus parameters (AAAAI/EAACI PRACTALL 2024 update) have standardized oral food challenge protocols to maximize safety and diagnostic precision:

• Dosing regimens employ semi-logarithmic incremental doses based on total food protein weight (e.g., $1\text{ mg}, 3\text{ mg}, 10\text{ mg}, 30\text{ mg}, 100\text{ mg}, 300\text{ mg}, 1000\text{ mg}$, and $3000\text{ mg}$).
• Dose administration occurs at fixed intervals of 20 to 30 minutes, ensuring adequate observation for immediate IgE-mediated reactions prior to escalation.
• Challenges are stopped upon the appearance of clear, objective clinical signs—such as localized urticaria, persistent cough, wheezing, repetitive vomiting, or hypotension. Standardized stopping criteria prevent progression to severe systemic anaphylaxis.

Therapeutic Management and Emerging Interventions

Management of established food allergy centers on targeted allergen avoidance. Elimination diets require detailed patient education on label reading, cross-contamination risks, and substitute foods. Pediatric dietary planning requires nutritional supervision to prevent growth impairment and micronutrient deficiencies.

For infants with cow's milk allergy (CMA) who cannot be exclusively breastfed, formula selection is guided by clinical guidelines (e.g., DRACMA update).

Intramuscular epinephrine is the first-line emergency treatment for systemic anaphylaxis. Epinephrine rapidly reverses peripheral vasodilation, reduces mucosal edema, relaxes bronchial smooth muscle, and inhibits further mast cell and basophil degranulation through beta-2 adrenergic signaling. Epinephrine is injected intramuscularly into the anterolateral mid-thigh at a dose of $0.01\text{ mg/kg}$ body weight (maximum single dose of $0.3\text{ mg}$ in pediatrics and $0.3\text{--}0.5\text{ mg}$ in adults), repeatable every 5 to 15 minutes if symptoms persist. Patients with severe reactions, co-existing asthma, or allergies to high-risk foods (peanuts, tree nuts, seafood) should carry two auto-injectors ($0.15\text{ mg}$ for pediatric patients weighing $7.5\text{--}25\text{ kg}$; $0.3\text{ mg}$ for individuals $>25\text{ kg}$) alongside a written Emergency Action Plan. Oral or parenteral $H_1$/$H_2$ antihistamines and systemic corticosteroids are adjunctive measures only. Antihistamines relieve cutaneous pruritus but do not reverse airway obstruction or cardiovascular collapse, while corticosteroids have a delayed onset ($>4\text{ hours}$) aimed at preventing biphasic reactions. Antihistamines or corticosteroids must never delay intramuscular epinephrine administration.

Management strategies have expanded from strict avoidance toward active disease-modifying immunotherapeutic options. Oral Immunotherapy (OIT) involves daily oral administration of escalating allergen doses over several months, shifting immune responses from a $T_H2$ profile toward $T_H1$ and regulatory T-cell ($T_{reg}$) responses, accompanied by increased allergen-specific IgG4 levels. Standardized OIT protocols for peanut, milk, and egg demonstrate desensitization success by raising reaction thresholds during active therapy. However, sustained unresponsiveness after treatment cessation remains variable, and OIT carries risks of systemic allergic reactions and secondary Eosinophilic Esophagitis.

Biological therapy with omalizumab—a humanized anti-IgE monoclonal antibody that binds free circulating IgE at the $C\epsilon 3$ domain—prevents IgE interaction with $Fc\epsilon RI$ receptors and downregulates receptor expression on mast cells and basophils. Omalizumab is approved as monotherapy and as an adjunct to OIT for single and multi-food allergies in patients aged 1 year and older. By elevating reaction thresholds, omalizumab protects against anaphylaxis from accidental cross-contact exposures. Furthermore, updated management guidelines highlight the necessity of screening for food allergy-related anxiety and psychosocial stress during routine visits, referring patients for specialized mental health support when indicated.

Primary Prevention Strategies

Primary prevention recommendations have evolved significantly, shifting from allergen avoidance toward deliberate early dietary introduction. Historical guidance advocating the postponement of allergenic food introduction until 2 to 3 years of age correlated with an increased incidence of food allergy. The dual-allergen-exposure hypothesis explains that allergic sensitization occurs through low-dose allergen exposure across a disrupted cutaneous barrier (e.g., in infantile eczema), whereas early high-dose oral exposure promotes gut-associated mucosal tolerance via $T_{reg}$ induction.

Current consensus guidelines (EAACI 2020 update, NIAID/AAAAI parameters) recommend introducing age-appropriate peanut products (e.g., thinned peanut butter or peanut puffs) and well-cooked hen's egg into the infant diet during complementary feeding, ideally between 4 and 6 months of age. This recommendation applies to both average-risk infants and high-risk infants with severe eczema or pre-existing egg allergy. Maternal dietary restrictions during pregnancy or lactation do not prevent childhood atopy and are discouraged. Exclusive breastfeeding is recommended for the first 4 to 6 months of life. However, routine supplementation of breastfed newborns with regular cow's milk formula during the first week of life should be avoided, as brief intermittent exposure to intact milk proteins can increase the risk of IgE sensitization.

Conclusion

Food hypersensitivity encompasses a spectrum of IgE-mediated, non-IgE-mediated, and mixed cell-mediated immunologic disorders that must be differentiated from non-immunologic food intolerances. Accurate diagnosis requires a comprehensive history paired with evidence-based diagnostics, including skin prick testing, serum-specific IgE decision thresholds, and standardized oral food challenges. Unvalidated testing panels must be avoided to prevent inappropriate dietary restriction. Clinical management has advanced from strict allergen avoidance to disease-modifying therapies—including oral immunotherapy and anti-IgE biologicals—alongside early infant allergen introduction to promote durable tolerance.